 |
市場調査レポート
商品コード
1455088
タンパク質治療薬の世界市場規模、シェア、成長分析、製品タイプ別、用途別、治療領域別 - 業界予測、2024年～2031年Global Protein Therapeutics Market Size, Share, Growth Analysis, By Product Type(Monoclonal Antibodies, Insulin), By Application (Oncology, Hematology), By Therapeutic Area(Cancer, Diabetes) - Industry Forecast 2024-2031 |
||||||
| タンパク質治療薬の世界市場規模、シェア、成長分析、製品タイプ別、用途別、治療領域別 - 業界予測、2024年～2031年 |
|
出版日: 2024年03月17日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のタンパク質治療薬市場規模は2022年に65億7,000万米ドルと評価され、2023年の69億6,000万米ドルから2031年には111億米ドルに成長し、予測期間中（2024年～2031年）のCAGRは6％で成長する見通しです。
タンパク質治療薬市場は、バイオ医薬品の領域拡大と慢性疾患の有病率の上昇に起因する大きな成長を経験しています。モノクローナル抗体、インスリン、ワクチンなどのタンパク質治療薬は、さまざまな病状の治療において重要な役割を果たし続けています。バイオテクノロジーにおける技術の進歩は、革新的なタンパク質ベースの製剤の出現と並んで、市場の拡大に大きく貢献しています。さらに、個別化医療や標的治療戦略の採用が増加していることも、高い製造コストや規制上のハードルといった課題にもかかわらず、需要を牽引しています。北米が依然として支配的である一方、アジア太平洋地域はヘルスケアインフラの改善と患者数の急増に後押しされ、急速に台頭しつつあります。主な動向としては、新規治療ターゲットの探索、タンパク質治療開発への先端技術の統合などが挙げられます。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
タンパク質治療薬の世界市場：製品タイプ別
- 市場概要
- モノクローナル抗体
- インスリン
- ワクチン
- 成長ホルモン
- 血液凝固因子
- 酵素補充療法
タンパク質治療薬の世界市場：用途別
- 市場概要
- 腫瘍学
- 血液学
- 免疫学
- 代謝障害
- 心血管疾患
- その他
タンパク質治療薬の世界市場：治療領域別
- 市場概要
- がん
- 糖尿病
- 感染症
- 自己免疫疾患
- 遺伝性疾患
- その他
タンパク質治療薬の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Amgen Inc.（US）
- AbbVie Inc.（US）
- Roche Diagnostics（Switzerland）
- Eli Lilly and Company（US）
- Johnson & Johnson（US）
- Pfizer Inc.（US）
- F. Hoffmann-La Roche Ltd（Switzerland）
- Novo Nordisk A/S（Denmark）
- Merck & Co., Inc.（US）
- Celgene Corporation（US）
- GlaxoSmithKline PLC（UK）
- Gilead Sciences, Inc.（US）
- Biogen Inc.（US）
- AstraZeneca PLC（UK）
- Takeda Pharmaceutical Company Limited（Japan）
- Abbott Laboratories（US）
- Bayer AG（Germany）
- Alexion Pharmaceuticals Inc.（US）
- Novartis AG（Switzerland）
- Sanofi（France）
Global Protein Therapeutics Market size was valued at USD 6.57 billion in 2022 and is poised to grow from USD 6.96 billion in 2023 to USD 11.10 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).
The Protein Therapeutics market is experiencing significant growth attributed to the expanding realm of biopharmaceuticals and the rising prevalence of chronic illnesses. Monoclonal antibodies, insulin, and vaccines, among other protein therapeutics, continue to serve as crucial components in treating various medical conditions. Technological advancements in biotechnology, alongside the emergence of innovative protein-based formulations, contribute significantly to market expansion. Moreover, the increasing adoption of personalized medicine and targeted treatment strategies drives demand, despite challenges such as high production costs and regulatory hurdles. While North America remains dominant, the Asia-Pacific region is rapidly emerging, propelled by improved healthcare infrastructure and burgeoning patient populations. Key trends include the exploration of novel therapeutic targets and the integration of advanced technologies into protein therapy development.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Protein Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Protein Therapeutics Market Segmental Analysis
The global Protein Therapeutics market is segmented into four major segments i.e. by Product Type, Application, Therapeutic Area, and region. Based on Type, it is divided into Monoclonal Antibodies, Insulin, Vaccines, Growth Hormones, Blood Clotting Factors, Enzyme Replacement Therapies. Based on Application, it is bifurcated as Oncology, Hematology, Immunology, Metabolic Disorders, Cardiovascular Disorders, Others. Based on Therapeutic Area it is segregated into Cancer, Diabetes, Infectious Diseases, Autoimmune Disorders, Genetic Disorders, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Drivers of the Global Protein Therapeutics Market
The increasing incidence of chronic ailments and intricate medical conditions underscores the significance of protein-based therapies, offering tailored and efficient solutions. The adaptability of protein therapeutics, encompassing monoclonal antibodies and other biologics, enables precise interventions across diverse therapeutic domains such as oncology, immunology, and metabolic disorders. Moreover, advancements in biotechnology and genetic engineering have paved the way for the creation of innovative and more potent protein therapeutics. As the demand for personalized medicine rises and the need for biopharmaceuticals with reduced side effects grows, there is a burgeoning inclination towards the adoption of protein-based treatments.
Restraints in the Global Protein Therapeutics Market
One of the main obstacles in the marketplace is the high cost linked with the development, production, and introduction of protein-based therapies. The intricate manufacturing processes and the requirement for sophisticated technologies contribute to inflated expenses, restricting accessibility, particularly in less affluent regions. Moreover, regulatory intricacies and rigorous approval procedures create hurdles, prolonging the time-to-market for protein therapeutics. Concerns regarding immunogenicity, wherein the patient's immune system may react to the therapeutic protein, further complicate matters.
Market Trends of the Global Protein Therapeutics Market
There is a noticeable shift towards personalized treatment in healthcare, particularly evident in the development of targeted protein therapeutics customized to individual patient characteristics. This trend is supported by advancements in next-generation biologics like antibody-drug conjugates and bispecific antibodies, offering more potent and adaptable therapeutic options. Additionally, advancements in protein engineering are enabling the creation of novel and optimized protein structures, thereby enhancing therapeutic effectiveness. The exploration of alternative delivery routes such as subcutaneous and oral administration is becoming increasingly popular, offering improved patient convenience.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Protein Therapeutics Market by Product Type
- Market Overview
- Monoclonal Antibodies
- Insulin
- Vaccines
- Growth Hormones
- Blood Clotting Factors
- Enzyme Replacement Therapies
Global Protein Therapeutics Market by Application
- Market Overview
- Oncology
- Hematology
- Immunology
- Metabolic Disorders
- Cardiovascular Disorders
- Others
Global Protein Therapeutics Market by Therapeutic Area
- Market Overview
- Cancer
- Diabetes
- Infectious Diseases
- Autoimmune Disorders
- Genetic Disorders
- Others
Global Protein Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
